Patents by Inventor Steven Brandon Thorpe

Steven Brandon Thorpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sphingosine kinase inhibitor amidoxime prodrugs
    Patent number: 12234229
    Abstract: Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: February 25, 2025
    Assignees: University of Virginia Patent Foundation, Virginia Tech Intellectual Properties, Inc.
    Inventors: Steven Brandon Thorpe, Webster L. Santos, Kevin R. Lynch
  • SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS
    Publication number: 20230050649
    Abstract: Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.
    Type: Application
    Filed: July 14, 2021
    Publication date: February 16, 2023
    Inventors: Steven Brandon Thorpe, Webster L. Santos, Kevin R. Lynch
  • Sphingosine kinase inhibitor amidoxime prodrugs
    Patent number: 11180489
    Abstract: Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: November 23, 2021
    Assignees: U niversity of Virginia Patent Foundation, Virginia Tech Entellectuzal Properties, Inc.
    Inventors: Steven Brandon Thorpe, Webster L. Santos, Kevin R. Lynch
  • SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS
    Publication number: 20200308159
    Abstract: Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.
    Type: Application
    Filed: March 29, 2017
    Publication date: October 1, 2020
    Inventors: Steven Brandon Thorpe, Webster L. Santos, Kevin R. Lynch